Erlotinib 100mg or 150mg in Treating EGFR Mutated NSCLC

Sponsor
The First Affiliated Hospital of Guangzhou Medical University
Study ID
NCT02140333
Phase
PHASE3
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to determine whether 100mg erlotinib had similar effect compared with 150mg erlotinib in NSCLC patients with EGFR mutation in China.

Key Dates

First listed
May 16, 2014
Start date
Aug 31, 2013
Status verified
Feb 2015
Primary completion
Aug 31, 2018
Completion
Dec 31, 2018

Study Design

Enrollment
220 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Erlotinib 100mg
    Erlotinib 100mg
  • Active Comparator: Erlotinib 150mg
    Erlotinib 150mg

Primary Outcome Measure

Progression free survival [ Time Frame: 2 years after the initial dose ]

Central Contacts

Related Studies